Cargando…
Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial
BACKGROUND: Acne vulgaris is considered one of the most common disorders for which patients seek dermatologic care. In the current study, we evaluated efficacy of the 5% nicotinamide gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris. MATERIALS AND METHODS: This was a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724370/ https://www.ncbi.nlm.nih.gov/pubmed/23914212 |
_version_ | 1782476682895032320 |
---|---|
author | Shahmoradi, Zabiolah Iraji, Farib Siadat, Amir Hossein Ghorbaini, Azamosadat |
author_facet | Shahmoradi, Zabiolah Iraji, Farib Siadat, Amir Hossein Ghorbaini, Azamosadat |
author_sort | Shahmoradi, Zabiolah |
collection | PubMed |
description | BACKGROUND: Acne vulgaris is considered one of the most common disorders for which patients seek dermatologic care. In the current study, we evaluated efficacy of the 5% nicotinamide gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris. MATERIALS AND METHODS: This was a randomized, controlled clinical trial that was performed in 2009-2010. Sixty female patients with mild or moderate acne vulgaris were recurited to be treated either with 5% nicotinamide or 2% clindamycin gel for 8 weeks. Acne severity index (ASI) was used to evaluate response to treatment and SPSS software was used to analyze the data. RESULTS: The mean of ASI at the baseline was 16.85 ± 8.5 and 18.2 ± 12.27 in nicotinamide gel and clindamycin gel, respectively (P > 0.05). The mean of ASI was significantly decreased compared with baseline ASI during the time in both groups (P < 0.0001). However, there was not a significant difference regarding reduction of ASI between the nicotinamide and clindamycin gel (P = 0.583). CONCLUSION: Five percent nicotinamide gel is as effective as 2% clindamycin gel for treatment of mild to moderate acne vulgaris. No side effect was observed during the treatment. |
format | Online Article Text |
id | pubmed-3724370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-37243702013-08-02 Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial Shahmoradi, Zabiolah Iraji, Farib Siadat, Amir Hossein Ghorbaini, Azamosadat J Res Med Sci Original Article BACKGROUND: Acne vulgaris is considered one of the most common disorders for which patients seek dermatologic care. In the current study, we evaluated efficacy of the 5% nicotinamide gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris. MATERIALS AND METHODS: This was a randomized, controlled clinical trial that was performed in 2009-2010. Sixty female patients with mild or moderate acne vulgaris were recurited to be treated either with 5% nicotinamide or 2% clindamycin gel for 8 weeks. Acne severity index (ASI) was used to evaluate response to treatment and SPSS software was used to analyze the data. RESULTS: The mean of ASI at the baseline was 16.85 ± 8.5 and 18.2 ± 12.27 in nicotinamide gel and clindamycin gel, respectively (P > 0.05). The mean of ASI was significantly decreased compared with baseline ASI during the time in both groups (P < 0.0001). However, there was not a significant difference regarding reduction of ASI between the nicotinamide and clindamycin gel (P = 0.583). CONCLUSION: Five percent nicotinamide gel is as effective as 2% clindamycin gel for treatment of mild to moderate acne vulgaris. No side effect was observed during the treatment. Medknow Publications & Media Pvt Ltd 2013-02 /pmc/articles/PMC3724370/ /pubmed/23914212 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Shahmoradi, Zabiolah Iraji, Farib Siadat, Amir Hossein Ghorbaini, Azamosadat Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial |
title | Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial |
title_full | Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial |
title_fullStr | Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial |
title_full_unstemmed | Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial |
title_short | Comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: A double-blinded randomized clinical trial |
title_sort | comparison of topical 5% nicotinamid gel versus 2% clindamycin gel in the treatment of the mild-moderate acne vulgaris: a double-blinded randomized clinical trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724370/ https://www.ncbi.nlm.nih.gov/pubmed/23914212 |
work_keys_str_mv | AT shahmoradizabiolah comparisonoftopical5nicotinamidgelversus2clindamycingelinthetreatmentofthemildmoderateacnevulgarisadoubleblindedrandomizedclinicaltrial AT irajifarib comparisonoftopical5nicotinamidgelversus2clindamycingelinthetreatmentofthemildmoderateacnevulgarisadoubleblindedrandomizedclinicaltrial AT siadatamirhossein comparisonoftopical5nicotinamidgelversus2clindamycingelinthetreatmentofthemildmoderateacnevulgarisadoubleblindedrandomizedclinicaltrial AT ghorbainiazamosadat comparisonoftopical5nicotinamidgelversus2clindamycingelinthetreatmentofthemildmoderateacnevulgarisadoubleblindedrandomizedclinicaltrial |